Physician profile
Sanjay Kaul
NPI 1992777866
$69,010.43
in general payments reported to CMS, 2019-2025
20 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $225 · 2021: $409 · 2022: $213 · 2023: $17K · 2024: $525 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,000.00 |
| Food and Beverage | $1,400.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim India Pvt. LTD. | $45,876.34 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16,000.00 | 2023 | |
| Boehringer Ingelheim Korea LTD. | $3,963.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $824.09 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $479.67 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Axsome Therapeutics, INC. | $403.02 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $325.70 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $260.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $203.46 | 2019-2024 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $138.16 | 2022-2025 | |
| Radius Health, INC. | $125.92 | 2019-2024 | Tymlos |
| Amarin Pharma, INC. | $92.59 | 2020-2021 | |
| Horizon Therapeutics Plc | $69.03 | 2019 | |
| Amgen INC. | $68.89 | 2019 | |
| Allergan, INC. | $66.94 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $50.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.33 | 2023 | |
| Idorsia Pharmaceuticals US INC | $18.33 | 2023 | Quviviq |
| Abbvie INC. | $13.92 | 2023 | |
| Phathom Pharmaceuticals, INC. | $6.94 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Kaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.